Ntroduction: Cariprazine (RGH-188) is a novel antipsychotic drug that exerts partial agonism of dopamine D2/D3 receptors with preferential binding to D3 receptor, antagonism of 5HT2B receptors and partial agonism of 5HT1A. Its interesting pharmacodynamic profile suggests its potential in the treatment of a plethora of psychiatric disorders. The present comprehensive review aims at summarizing the current evidence about the safety, tolerability and efficacy of Cariprazine in the treatment of schizophrenia, BD (manic/mixed/depressive episode) and MDD. EVIDENCEACQUISITION: Aliterature search was here carried out on PubMed/Medline/Scopus and the database on Clinical Trials from inception until December 2015 by typing a set of specified keywords. EVIDENCE SYNTHESIS: Cariprazine appears to be efficacy in the treatment of cognitive and negative symptoms of schizophrenia. Preliminary findings suggest its antimanic activity whilst it is still under investigation its efficacy in the treatment of bipolar depression and MDD. CONCLUSIONS: Further studies should be needed in order to better identify its clinical efficacy profile.

Cariprazine (RGH-188). A new pharmacological target option for the treatment of schizophrenia, bipolar disorders and depression? / Orsolini, L.; Iasevoli, F.; Prinzivalli, E.; Valchera, A.; Fornaro, M.; Vecchiotti, R.; Latini, R.; Carano, A.; Pompili, M.; Perna, G.; Vellante, F.; Matarazzo, I.; Martinotti, G.; Debartolomeis, A.; Digiannantonio, M.; De Berardis, D.. - In: MINERVA PSICHIATRICA. - ISSN 0391-1772. - 58:1(2017), pp. 17-25. [10.23736/S0391-1772.17.01920-3]

Cariprazine (RGH-188). A new pharmacological target option for the treatment of schizophrenia, bipolar disorders and depression?

Pompili M.;
2017

Abstract

Ntroduction: Cariprazine (RGH-188) is a novel antipsychotic drug that exerts partial agonism of dopamine D2/D3 receptors with preferential binding to D3 receptor, antagonism of 5HT2B receptors and partial agonism of 5HT1A. Its interesting pharmacodynamic profile suggests its potential in the treatment of a plethora of psychiatric disorders. The present comprehensive review aims at summarizing the current evidence about the safety, tolerability and efficacy of Cariprazine in the treatment of schizophrenia, BD (manic/mixed/depressive episode) and MDD. EVIDENCEACQUISITION: Aliterature search was here carried out on PubMed/Medline/Scopus and the database on Clinical Trials from inception until December 2015 by typing a set of specified keywords. EVIDENCE SYNTHESIS: Cariprazine appears to be efficacy in the treatment of cognitive and negative symptoms of schizophrenia. Preliminary findings suggest its antimanic activity whilst it is still under investigation its efficacy in the treatment of bipolar depression and MDD. CONCLUSIONS: Further studies should be needed in order to better identify its clinical efficacy profile.
2017
antipsychotic agents; bipolar disorder; cariprazine; depressive disorder; dopamine; major; schizophrenia
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Cariprazine (RGH-188). A new pharmacological target option for the treatment of schizophrenia, bipolar disorders and depression? / Orsolini, L.; Iasevoli, F.; Prinzivalli, E.; Valchera, A.; Fornaro, M.; Vecchiotti, R.; Latini, R.; Carano, A.; Pompili, M.; Perna, G.; Vellante, F.; Matarazzo, I.; Martinotti, G.; Debartolomeis, A.; Digiannantonio, M.; De Berardis, D.. - In: MINERVA PSICHIATRICA. - ISSN 0391-1772. - 58:1(2017), pp. 17-25. [10.23736/S0391-1772.17.01920-3]
File allegati a questo prodotto
File Dimensione Formato  
Orsolini_Cariprazine_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 6.2 MB
Formato Adobe PDF
6.2 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1521242
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact